The issue of health service planning regularly hits the headlines. In a speech delivered in October by the Chief Executive of NHS England, Simon Stevens described a “mismatch between resources and patient needs of nearly £30 billion a year by 2020/21”.
This OHE Occasional Paper by Adrian Towse discusses Professor Bengt Jönsson’s observations in a 2011 publication about the role of relative effectiveness research (RE) in the European medicines market and how this could lead to improved efficiency in the development of medicines, the pricing and use of medicines, and of health systems.
Economic thinking and analysis can contribute greatly to designing and evaluating health care policy and practice. There is a growing need to improve the efficiency and sustainability of health care systems everywhere.
The cost of the National Health Service in the United Kingdom now exceeds £l,000m. per year. Ten years ago, when expenditure was less than half this amount, the cost of the Health Service was the source of continued public concern. Cost was "the one aspect of the National Health Service which, since its inception in 1948, has given rise to more critical discussion and controversy than any other single issue". The controversy has now largely died away, and expenditure on the Service is no longer viewed with such alarm or disquiet.
The total expenditure on medicines in the United Kingdom in 1966 was £267 million. Of this £188 million was for medicines prescribed on the National Health Service. The other £79 million was spent by the public mainly for medicines bought without a doctor's prescription. Thus self-treatment still forms an important aspect of medical care, although in terms of cost it accounts for less than half per cent of total consumer expenditure.
Lewis, F., Karlsberg Schaffer, S., Sussex, J., O'Neill, P. and Cockcroft, L.
Alzheimer’s Research UK commissioned OHE Consulting to model the incidence and cost of dementia in the UK and the potential impact of better treatment. The analyses estimate the extent of the substantial reductions in health and social care costs that are possible to 2050.
Karlsberg Schaffer, S., Sussex, J., Hughes, D. and Devlin, N.
This new research from the OHE examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies recommended by NICE within three months after NICE publishes a Technology Appraisal (TA). Based on interviews with medical and/or finance directors of the seven Wales LHBs, the study covers the period from October 2010 through March 2013.
Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, considers the current use of cost-effectiveness analysis in the US and explores the potential value of including it in decisions about coverage for medical technology by Medicare (the national public health insurance programme primarily for people 65+ years of age).
This monograph, based on Professor Maynard’s remarks at the 20th OHE Annual Lecture, explores the critical issue of ensuring the quality of care in the NHS. The lecture was delivered just five months after release of the Francis Report, which was the result of a public inquiry into serious failures in patient care at the Mid Staffordshire NHS Foundation Trust. As with many such inquiries in the past, Francis’s recommendations envisioned more regulation.